16 Nov 2021 Research
John Goldman Fellowships for 2022 open in December
Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2022, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman Fellowships.
Applications for the annual fellowship programme open on 1st December 2021 to scientists and clinician-scientists working in UK universities, research institutions or hospitals. There is no age limit, although the fellowship programme is designed to provide funding at a critical point in a researcher’s career – the transition to becoming an independent researcher.
We have now increased the maximum award available to £150,000, to span a minimum 18-month and maximum 2-year period.
The John Goldman Fellowships were created in honour of Professor John Goldman (1938 – 2013), a renowned haematologist and pioneer in the treatment of leukaemia.
The awards are aimed at early career researchers with a passion for science, a desire to develop new ideas and translate scientific advances into clinical practice.
Successful applicants will show that they are the potential scientific/clinical leaders of the future. Their proposed research project must be novel with the capacity to make advances in our knowledge of leukaemia and related diseases and the development of new and kinder treatments.
Find out more about the 2021 John Goldman Fellows and their research projects:
Dr Daniel Coleman- AML: Developing kinder treatments by targeting mutated RAS
Dr Pramila Krishnamurthy – Understanding how donor lymphocyte infusion can prevent leukaemia patients from relapsing after a stem cell transplant
Dr Samanta Mariani – Investigating the role of macrophages in infant leukaemia
Dr William Grey (pictured above) – Could targeting the repertoire of proteins in AML lead to improved survival for the most at risk patients?
Dr Giulia Orlando (pictured right) – The role of RAS in Juvenile Myelomonocytic Leukaemia-finding new therapies?
Applications for the 2022 fellowships close on 31st January 2022. Find out more about the application process.
Related posts
16 November 2022
Leukaemia UK and Leukaemia Care urge benefits to be raised in line with inflation
Leukaemia UK and Leukaemia Care have written to the Chancellor to highlight the additional financial pressures faced by blood cancer patients and their families, ahead of the Autumn Statement this…
30 June 2023
New book ‘Bronty’s Battle Cry’ supports Leukaemia UK
‘Bronty’s Battle Cry,’ an inspiring new picture book written by award-winning children’s author and young person’s counsellor, Hannah Peckham, has recently launched and Leukaemia UK are delighted that some of…
25 August 2020
Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK
After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.
25 November 2025
Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl
Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…